This program will highlight a different approach to the treatment of heart failure with reduced ejection fraction (HFrEF). By targeting a mechanism of action aligned to pathophysiologic pathways, it is possible to reduce patient mortality and morbidity, while providing a proven safety and tolerability profile to help provide confidence in selecting your first-choice therapy for patients with HFrEF.

Join us as we examine the risk of hospitalization for heart failure (HF) among patients with type 2 diabetes (T2D) and explore evidence-based risk reduction strategies that you can incorporate into your practice. We will discuss the results of the DECLARE trial, the largest cardiovascular (CV) outcomes trial to study hospitalization for HF reduction in patients with T2D and established CV disease or multiple CV risk factors. We'll also discuss the results of the landmark DAPA-HF trial that support FARXIGA being the FIRST and ONLY FDA-approved sodium-glucose cotransporter 2 inhibitor (SGLT2) for patients with HF with reduced ejection fraction (HFrEF) with and without T2D.

Come join Dr. Scott Tiplitsky in exploration of our topic: Identifying, Engaging, and Treating Erectile Dysfunction.

CDC Resources for Health Care Providers

Opioids are an important therapy for the management of pain in older patients with cancer-related chronic pain, as well as in some with chronic noncancer pain. This program reviews important concepts in initiating and continuing opioid therapy in older patients. This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://ce.opioidanalgesicrems.com/RpcCEUI/rems/pdf/resources/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the US Food and Drug Administration (FDA). ​

Join Dr. Charles Vega and Ashton Hyde, Esq. as they reveal the most common reasons for malpractice suits in primary care and discuss what you can do in daily practice to protect your patients from medical errors and yourselves from lawsuits. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on 7/21/2020, and they are subject to change as new information is published.

In the fourteenth episode of Pri-Med’s weekly web series on COVID-19, faculty will discuss the recent data on COVID-19 and children. This presentation will cover the typical presentation of COVID-19 in children and review the risk and mechanisms of Multisystem Inflammatory Syndrome in Children (MIS-C).

Test your knowledge on severe asthma with this interactive game of Jeopardy! Learn about diagnosis, biomarkers and assessment tools, medications and management, asthma heterogeneity, and associated conditions as you try to get a high score! Please note that any data, indications, and guidelines presented in this activity are current as of 7/2/2020 and they are subject to change as new information is published.